Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.56 is 96% above its 5-year average of -107.32, near the high end of its 5-year range (-228.55–-4.56).
79.67% above its 12-month average of -22.43.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.57.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 37 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.56
EARNINGS PER SHARE (EPS) AVG TTM
-22.43
EARNINGS PER SHARE (EPS) AVG 3Y
-71.26
EARNINGS PER SHARE (EPS) AVG 5Y
-107.32
EARNINGS PER SHARE (EPS) AVG 10Y
-3043.89
EARNINGS PER SHARE (EPS) AVG 15Y
-24184.48
EARNINGS PER SHARE (EPS) AVG 20Y
-2426143.49
CURRENT VS TTM AVG
+79.67%
CURRENT VS 3Y AVG
+93.60%
CURRENT VS 5Y AVG
+95.75%
CURRENT VS 10Y AVG
+99.85%
CURRENT VS 15Y AVG
+99.98%
CURRENT VS 20Y AVG
+100.00%
Cellectar Biosciences, Inc.
Market Cap
$13.34M
Earnings Per Share (EPS)
-4.56
TTM Avg
-22.43
3Y Avg
-71.26
5Y Avg
-107.32
Market Cap
$12.63M
Earnings Per Share (EPS)
-0.79
TTM Avg
-0.84
3Y Avg
-2.55
5Y Avg
-4.78
Market Cap
$12.46M
Earnings Per Share (EPS)
-5.75
TTM Avg
-5.10
3Y Avg
-9.55
5Y Avg
-8.93
Market Cap
$14.28M
Earnings Per Share (EPS)
-2.11
TTM Avg
-3.38
3Y Avg
-4.90
5Y Avg
-6.31
Market Cap
$11.95M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.21
3Y Avg
-0.25
5Y Avg
-0.25
Market Cap
$11.42M
Earnings Per Share (EPS)
-16.53
TTM Avg
-14.84
3Y Avg
-116.30
5Y Avg
-277.16
Market Cap
$11.41M
Earnings Per Share (EPS)
-0.60
TTM Avg
-2.13
3Y Avg
-4.47
5Y Avg
-13.49
Market Cap
$15.30M
Earnings Per Share (EPS)
-0.77
TTM Avg
-1.25
3Y Avg
-1.82
5Y Avg
-1.86
Market Cap
$11.01M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.74
3Y Avg
-0.71
5Y Avg
-0.50
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.34M | -4.56 | -22.43 | -71.26 | -107.32 |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -0.79 | -0.84 | -2.55 | -4.78 |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -5.75 | -5.10 | -9.55 | -8.93 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -2.11 | -3.38 | -4.90 | -6.31 |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | -0.21 | -0.25 | -0.25 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | -16.53 | -14.84 | -116.30 | -277.16 |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -0.60 | -2.13 | -4.47 | -13.49 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -0.77 | -1.25 | -1.82 | -1.86 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -0.47 | -0.74 | -0.71 | -0.50 |
| BioVie Inc. (BIVI)vs › | $10.86M | -3.20 | -7.58 | -60.73 | -69.78 |
Trailing EPS (TTM)
$-4.56
Forward EPS (Est.)
$-2.43
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -8.35 |
| 2024-12-31 | -36.52 |
| 2023-12-31 | -104.99 |
| 2022-12-31 | -135.18 |
| 2021-12-31 | -130.35 |
| 2020-12-31 | -228.55 |
| 2019-12-31 | -550.86 |
| 2018-12-31 | -1567.96 |
| 2017-12-31 | -3210.00 |
| 2016-12-31 | -6420.00 |
| 2015-12-31 | -21090.00 |
| 2014-12-31 | -53100.00 |
| 2013-12-31 | -114000.00 |
| 2012-12-31 | -138000.00 |
| 2011-12-31 | -186000.00 |
| 2010-12-31 | -9180000.00 |
| 2009-12-31 | -48654000.00 |
| 2008-12-31 | -51408000.00 |
| 2007-12-31 | -69768000.00 |
| 2006-12-31 | -21114000.00 |
| 2005-12-31 | -12852000.00 |
| 2004-12-31 | -183600.00 |
